Published in N Engl J Med on October 30, 1975
Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors. J Exp Med (1976) 5.50
Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus. J Clin Invest (1977) 5.09
Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell. J Exp Med (1977) 4.59
Quantitative measurements of T- and B-cell function in "variable" primary hypogammaglobulinaemia: evidence for a consistent B-cell defect. Clin Exp Immunol (1977) 2.62
Direct evidence for loss of human suppressor cells during active autoimmune disease. Proc Natl Acad Sci U S A (1978) 2.32
Prostaglandin suppression of mitogen-stimulated lymphocytes in vitro. Changes with mitogen dose and preincubation. J Clin Invest (1978) 2.13
Changes in lymphocyte activity after thermal injury. The role of suppressor cells. J Clin Invest (1979) 1.94
Decreased suppressor cell activity in inflammatory bowel disease. Clin Exp Immunol (1978) 1.75
Regulation of B-lymphocyte clonal proliferation by stimulatory and inhibitory macrophage-derived factors. J Exp Med (1977) 1.67
Alteration in suppressor cell activity in chronic active hepatitis. Proc Natl Acad Sci U S A (1978) 1.57
Loss of suppressor T-lymphocyte function in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol (1978) 1.54
Suppression of immunoglobulin synthesis and secretion by peripheral blood lymphocytes from normal donors. Proc Natl Acad Sci U S A (1977) 1.50
In vitro studies of suppressor cell function in human peripheral blood mononuclear cells. Clin Exp Immunol (1978) 1.39
Impaired cell-mediated immunity in Hodgkin's disease mediated by suppressor lymphocytes and monocytes. J Clin Invest (1978) 1.31
The requirement of an adherent cell substratum for the growth of developing plasmacytoma cells in vivo. J Exp Med (1976) 1.27
Inhibition of polyclonal B-cell activation by suppressor monocytes in patients with sarcoidosis. Clin Exp Immunol (1978) 1.25
Lymphocyte suppressor cell activity in acute and chronic liver disease. Clin Exp Immunol (1981) 1.24
Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B-cell activation. Immunology (1980) 1.24
Behaviour of human immunoregulatory cells in culture. I. Variables requiring consideration for clinical studies. Clin Exp Immunol (1979) 1.16
Studies of cell subpopulations mediating mitogen hyporesponsiveness in patients with Hodgkin's disease. J Clin Invest (1978) 1.16
The use of concanavalin A to study the immunoregulation of human T cells. Clin Exp Immunol (1981) 1.15
New concepts in the pathogenesis of primary and secondary amyloid disease. Clin Exp Immunol (1978) 1.11
Use of a human plaque-forming cell assay to study peripheral blood bursa-equivalent cell activation and excessive suppressor cell activity in humoral immunodeficiency. J Clin Invest (1979) 1.11
Modulatory effects on immunoglobulin synthesis and secretion by lymphocytes from immunodeficient patients. J Clin Invest (1977) 1.11
Immunoregulatory T cell function in multiple myeloma. J Clin Invest (1981) 1.10
Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia (2013) 1.08
Intracytoplasmic and surface-bound immunoglobulins in "nonsecretory" and Bence-Jones myeloma. Clin Exp Immunol (1976) 1.05
Spectrum of immunodeficiencies with Hodgkin's disease. J Clin Invest (1980) 1.05
Suppression of BCG cell wall induced delayed-type hypersensitivity by BCG pre-treatment. I. Induction of adherent suppressor cells by live BCG injection and their characterization. Immunology (1981) 1.04
Hypogammaglobulinaemia associated with abnormalities of both B and T lymphocytes in patients with chronic lymphatic leukaemia. Clin Exp Immunol (1980) 1.02
Studies on the pathogenesis of an immune defect in multiple myeloma. J Clin Invest (1977) 1.01
Decreased T lymphocyte migration in patients with malignancy mediated by a suppressor cell population. J Clin Invest (1984) 0.99
Suppressor cell-mediated neutropenia in Felty's syndrome. J Clin Invest (1978) 0.98
Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immun (2010) 0.97
Suppression of DNA synthesis by Con A-activated human lymphocytes: Stimulation by con A bound to non-T cells unless removed after activation. Clin Exp Immunol (1977) 0.97
Depressed primary in vitro antibody response in rheumatoid arthritis. Clin Exp Immunol (1979) 0.97
Membrane phenotype and functional behaviour of T lymphocytes in multiple myeloma: correlation with clinical stages of the disease. Clin Exp Immunol (1984) 0.95
Laboratory investigation of monoclonal gammopathy during 10 years of screening in a general hospital. J Clin Pathol (1987) 0.95
Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica (2011) 0.94
Diminished synthesis of immunoglobulin by peripheral lymphocytes of patients with idiopathic membranous glomerulonephropathy. J Clin Invest (1980) 0.93
Inhibition of suppressor T cells in pokeweed mitogen-stimulated cultures of T and B cells by levamisole in vitro and in vivo. Clin Exp Immunol (1981) 0.92
Apparent direct cellular cytotoxicity mediated via cytophilic antibody. Multiple Fc receptor bearing effector cell populations mediating cytophilic antibody induced cytotoxicity. Immunology (1977) 0.91
Hypogammaglobulinemia: therapeutic rationale. CMAJ (1987) 0.87
The regulation of T cell responses by spontaneously active suppressor cells. Clin Exp Immunol (1982) 0.87
The mode of action of splenic suppressor cells in murine plasmacytoma. Clin Exp Immunol (1981) 0.86
Abnormal function of B lymphocytes from peripheral blood of multiple myeloma patients. Lack of correlation between the number of cells potentially able to secrete immunoglobulin M and serum immunoglobulin M levels. J Clin Invest (1985) 0.86
Bacterial lipopolysaccharide-induced immunoglobulin synthesis by human blood lymphocytes partially depleted of monocytes. Clin Exp Immunol (1982) 0.86
Studies on the origin of the precursor cells in multiple myeloma, Waldenström's macroglobulinaemia and benign monoclonal gammopathy. I. Cytoplasmic isotype and idiotype distribution in peripheral blood and bone marrow. Clin Exp Immunol (1981) 0.86
Possible role of macrophage-like suppressor cells in the anti-tumour activity of BCG. Br J Cancer (1981) 0.85
In vitro immune cell function in six cases of immunoproliferative small intestinal disease after long term remission. Clin Exp Immunol (1983) 0.85
Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16. J Clin Invest (1995) 0.84
The metabolism of IgE in patients with immunodeficiency states and neoplastic conditions. J Clin Invest (1977) 0.84
Paraproteinaemia: use of idiotypic determinants as specific markers for tumour activity. Clin Exp Immunol (1981) 0.84
Monocyte suppression of Fusobacterium nucleatum-induced human polyclonal B-lymphocyte activation. Infect Immun (1984) 0.83
Multiple myeloma: ecto-5' nucleotidase deficiency of suppressor/cytotoxic (CD8) lymphocytes is a marker for the expansion of suppressor T cells. Clin Exp Immunol (1987) 0.83
Production of interleukin 2 in multiple myeloma. Clin Exp Immunol (1986) 0.82
In vitro suppression of T-cell mitogenic response and tumor cell proliferation by spleen macrophages from normal chickens. Infect Immun (1980) 0.82
Increased concanavalin A induced suppression in treated and untreated coeliac disease. Gut (1984) 0.81
Functional behaviour and immunological phenotype of circulating B lymphocytes in multiple myeloma. Studies with pokeweed mitogen. Clin Exp Immunol (1984) 0.81
The effect of an IgM plasmacytoma (TEPC-183) on the primary immune response of BALB/c mice. Immunology (1978) 0.78
Diffusible suppressor factor from splenic macrophages in murine plasmacytoma. Clin Exp Immunol (1984) 0.78
The relationship between hypogammaglobulinemia, monoclonal gammopathy of undetermined significance and humoral immunodeficiency: a case series. J Clin Immunol (2011) 0.78
Impairment of neutrophil chemotaxis by serum from patients with chronic lymphoproliferative disease. J Clin Pathol (1983) 0.78
The role of T, B and adherent cells in the in vitro immune response of TEPC-183-bearing mice. Immunology (1982) 0.78
Suppression of polyclonal B cell proliferation mediated by supernatants from human myeloma bone marrow cell cultures. Clin Exp Immunol (1989) 0.75
Participation of a histamine-Sepharose-adherent subpopulation of human mononuclear cells in the production of leucocyte migration inhibition factor (LIF) in healthy children. Clin Exp Immunol (1979) 0.75
Defective immunoglobulin secretion in response to pokeweed mitogen in sarcoidosis. Clin Exp Immunol (1982) 0.75
Metabolism of IgG in type II mixed essential cryoglobulinaemia--autologous cryoprecipitated and normal homologous IgG are incorporated into complexes and metabolized in vivo at similar rates. Clin Exp Immunol (1983) 0.75
Regulation of immunoglobulin synthesis by monocytes in multiple myeloma and benign monoclonal gammopathy. Clin Exp Immunol (1986) 0.75
Diseases associated with immunosuppression. Environ Health Perspect (1982) 0.75
Antigen stimulated IgM secretion by circulating B lymphocytes in patients with benign and malignant IgG gammopathy. Relationship to stage of disease. Clin Exp Immunol (1989) 0.75
Streptococcus pneumoniae bacteraemia leading to the diagnosis of multiple myeloma. BMJ Case Rep (2014) 0.75
Suppressor-cell functions in bullous pemphigoid. Arch Dermatol Res (1985) 0.75
Mechanisms in secondary hypogammaglobulinaemia. J Clin Pathol Suppl (R Coll Pathol) (1979) 0.75
Immunosuppression in plasmacytoma: induction of suppressor cells. Clin Exp Immunol (1982) 0.75
The sequence of the human genome. Science (2001) 101.55
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol (1981) 10.92
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Structure of the human immunoglobulin mu locus: characterization of embryonic and rearranged J and D genes. Cell (1981) 9.09
Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med (2001) 8.69
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia. Lancet (1974) 8.13
Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med (1995) 6.89
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol (2010) 5.91
Metabolism of immunoglobulins. Prog Allergy (1969) 5.74
Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest (1998) 5.70
Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell (1995) 5.64
Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A (1987) 5.17
Molecular targets for AIDS therapy. Science (1990) 4.28
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science (1986) 4.17
Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med (1996) 4.09
A T cell receptor V beta segment that imparts reactivity to a class II major histocompatibility complex product. Cell (1987) 4.09
Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med (1998) 3.50
The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia. J Clin Invest (1972) 3.43
A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med (1984) 3.41
The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells. J Exp Med (1990) 3.31
Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase. J Biol Chem (1983) 3.31
T-cell regulation of murine IgA synthesis. J Exp Med (1979) 3.11
Predominance of histocompatibility antigen HL-A8 in patients with gluten-sensitive enteropathy. J Clin Invest (1972) 3.09
The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med (1967) 3.06
Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science (1988) 3.01
Human immunoglobulin D segments encoded in tandem multigenic families. Nature (1981) 2.99
Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann Surg (2001) 2.96
Strategies for antiviral therapy in AIDS. Nature (1987) 2.95
Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol (1999) 2.92
Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther (1987) 2.92
Accelerated breakdown of immunoglobulin G (IgG) in myotonic dystrophy: a hereditary error of immunoglobulin catabolism. J Clin Invest (1966) 2.91
Two better cell lines for making hybridomas expressing specific T cell receptors. J Immunol (1989) 2.78
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science (1989) 2.70
Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science (1984) 2.70
Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med (1996) 2.68
The effector cells in human peripheral blood mediating mitogen-induced cellular cytotoxicity and antibody-dependent cellular cytotoxicity. J Immunol (1976) 2.65
NIH conference. Gastrointestinal infections in AIDS. Ann Intern Med (1992) 2.62
Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A (1989) 2.62
The Wiskott-Aldrich syndrome. A disorder with a possible defect in antigen processing or recognition. Lancet (1968) 2.61
NIH conference. New insights into common variable immunodeficiency. Ann Intern Med (1993) 2.52
Ataxia-telangiectasia. Medicine (Baltimore) (1972) 2.50
Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol (1993) 2.48
Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat Immunol (2001) 2.42
Distinct populations of dendritic cells are present in the subepithelial dome and T cell regions of the murine Peyer's patch. J Exp Med (1996) 2.38
CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med (1991) 2.35
Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol (1997) 2.35
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol (2013) 2.34
Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci U S A (1998) 2.33
The Sézary syndrome: a malignant proliferation of helper T cells. J Clin Invest (1976) 2.32
Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med (1996) 2.30
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest (1993) 2.27
Dermatitis herpetiformis: the skin and the gut. Ann Intern Med (1980) 2.24
An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med (1999) 2.20
The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med (1996) 2.17
Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity (1995) 2.17
TNBS-colitis. Int Rev Immunol (2000) 2.17
Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med (1989) 2.17
Fraud in breast-cancer trials. N Engl J Med (1994) 2.16
The murine Kupffer cell. I. Characterization of the cell serving accessory function in antigen-specific T cell proliferation. J Immunol (1979) 2.15
Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology (1999) 2.15
A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest (1992) 2.13
Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood (1997) 2.10
NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Intern Med (1984) 2.10
Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol (1987) 2.10
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med (2001) 2.10
Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med (1994) 2.07
Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis (1999) 2.03
Simultaneous induction of antigen-specific IgA helper T cells and IgG suppressor T cells in the murine Peyer's patch after protein feeding. J Immunol (1981) 2.03
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet (1990) 2.02
Incorporation of L-leucine-14C into immunoglobulins by jejunal biopsies of patients with celiac sprue and other gastrointestinal diseases. J Clin Invest (1971) 2.01
Suppressor cells in the regulation of the immune response. Prog Clin Immunol (1977) 1.99
Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. Proc Natl Acad Sci U S A (1987) 1.96
Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci U S A (1993) 1.92
The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner. Genes Dev (2000) 1.91
Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst (1991) 1.91
Intestinal lymphangiectasia: a protein-losing enteropathy with hypogammaglobulinemia, lymphocytopenia and impaired homograft rejection. J Clin Invest (1967) 1.88
Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. N Engl J Med (1987) 1.88
Gluten-sensitive enteropathy: synthesis of antigliadin antibody in vitro. Gut (1974) 1.87
Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther (1990) 1.87
Infections in patients with immunodeficiency with thymoma (Good syndrome). Report of 5 cases and review of the literature. Medicine (Baltimore) (2001) 1.86
Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system. Adv Immunol (1982) 1.85
Studies on the mechanism of human immunodeficiency virus reverse transcriptase. Steady-state kinetics, processivity, and polynucleotide inhibition. J Biol Chem (1988) 1.82
Compartmentation of protein folding in vivo: sequestration of non-native polypeptide by the chaperonin-GimC system. EMBO J (1999) 1.80
Fc-receptors on human T lymphocytes. I. Transition of Tgamma to Tmu cells. J Immunol (1978) 1.79
Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity. Ann Intern Med (1978) 1.78
Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology (1999) 1.78
The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J Clin Invest (1998) 1.77
An in vitro model of gluten-sensitive enteropathy. Effect of gliadin on intestinal epithelial cells of patients with gluten-sensitive enteropathy in organ culture. J Clin Invest (1974) 1.74
Functional properties of antigen-specific T cells infected by human T-cell leukemia-lymphoma virus (HTLV-I). Science (1984) 1.74
The role of IL-5 in IgA B cell differentiation. J Immunol (1988) 1.73